David Allen Schwartz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5758590/publications.pdf

Version: 2024-02-01

75 papers 3,106 citations

30 h-index 54 g-index

78 all docs 78 docs citations

78 times ranked 3354 citing authors

#	Article	IF	CITATIONS
1	Demographic Factors Associated With Successful Telehealth Visits in Inflammatory Bowel Disease Patients. Inflammatory Bowel Diseases, 2022, 28, 358-363.	1.9	12
2	Efficacy and Safety of 2 Vedolizumab Intravenous Regimens for Perianal Fistulizing Crohn's Disease: ENTERPRISE Study. Clinical Gastroenterology and Hepatology, 2022, 20, 1059-1067.e9.	4.4	33
3	Health Care Costs and Resource Utilization Among Patients With Crohn's Disease With and Without Perianal Fistula. Inflammatory Bowel Diseases, 2022, 28, 870-877.	1.9	11
4	Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium. The Lancet Gastroenterology and Hepatology, 2022, 7, 69-95.	8.1	41
5	A patient education intervention improved rates of successful video visits during rapid implementation of telehealth. Journal of Telemedicine and Telecare, 2021, , 1357633X2110087.	2.7	12
6	Endoscopic evaluation of surgically altered bowel in inflammatory bowel disease: a consensus guideline from the Global Interventional Inflammatory Bowel Disease Group. The Lancet Gastroenterology and Hepatology, 2021, 6, 482-497.	8.1	28
7	Patterns of endoscopy during COVID-19 pandemic: a global survey of interventional inflammatory bowel disease practice. Intestinal Research, 2021, 19, 332-340.	2.6	8
8	Safety and Efficacy of Vedolizumab Versus Tumor Necrosis Factor \hat{l}_{\pm} Antagonists in an Elderly IBD Population: A Single Institution Retrospective Experience. Digestive Diseases and Sciences, 2021, , 1.	2.3	11
9	Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International leal Pouch Consortium. The Lancet Gastroenterology and Hepatology, 2021, 6, 826-849.	8.1	69
10	Inpatient Management of Inflammatory Bowel Disease-Related Complications. Clinical Gastroenterology and Hepatology, 2020, 18, 1346-1355.	4.4	21
11	Assessing Severity of Disease in Patients with Ulcerative Colitis. Gastroenterology Clinics of North America, 2020, 49, 671-688.	2.2	49
12	Gastroenterologist-Lead Management of Iron Deficiency Anemia in Inflammatory Bowel Disease Is Effective, Safe, and May Increase Quality of Life. Crohn's & Colitis 360, 2020, 2, otaa051.	1.1	5
13	Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group. The Lancet Gastroenterology and Hepatology, 2020, 5, 393-405.	8.1	78
14	Precision nicotine metabolism-informed care for smoking cessation in Crohn's disease: A pilot study. PLoS ONE, 2020, 15, e0230656.	2.5	7
15	Prevalence of Fistulizing Crohn's Disease in the United States: Estimate From a Systematic Literature Review Attempt and Population-Based Database Analysis. Inflammatory Bowel Diseases, 2019, 25, 1773-1779.	1.9	53
16	Serum Polyunsaturated Fatty Acids Correlate with Serum Cytokines and Clinical Disease Activity in Crohn's Disease. Scientific Reports, 2019, 9, 2882.	3.3	41
17	Histoplasmosis as a Complication of Inflammatory Bowel Disease Therapy: A Case Series. Inflammatory Bowel Diseases, 2019, 25, e69-e70.	1.9	4
18	Role of interventional inflammatory bowel disease in the era of biologic therapy: a position statement from the Global Interventional IBD Group. Gastrointestinal Endoscopy, 2019, 89, 215-237.	1.0	61

#	Article	IF	CITATIONS
19	Management of Pouchitis and Other Common Complications of the Pouch. Inflammatory Bowel Diseases, 2018, 24, 989-996.	1.9	61
20	Alterations in lipid, amino acid, and energy metabolism distinguish Crohn's disease from ulcerative colitis and control subjects by serum metabolomic profiling. Metabolomics, 2018, 14, 17.	3.0	137
21	Challenges in Using Real-world Clinical Practice Records for Validation of Clinical Trial Data in Inflammatory Bowel Disease: Lessons Learned. Inflammatory Bowel Diseases, 2018, 24, 2-4.	1.9	4
22	Adherence rates and health care costs in Crohn's disease patients receiving certolizumab pegol with and without home health nurse assistance: results from a retrospective analysis of patient claims and home health nurse data. Patient Preference and Adherence, 2018, Volume 12, 869-878.	1.8	7
23	White Paper AGA: The Impact of Mental and Psychosocial Factors on the Care of Patients With Inflammatory BowelÂDisease. Clinical Gastroenterology and Hepatology, 2017, 15, 986-997.	4.4	83
24	Current management of perianal Crohn's disease. Current Problems in Surgery, 2017, 54, 262-298.	1.1	9
25	Depressive Symptoms Predict Anti-tumor Necrosis Factor Therapy Noncompliance in Patients with Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2017, 62, 3563-3567.	2.3	23
26	Comparison of Health Care Utilization and Costs Between Patients with Perianal Fistulizing Crohn $\hat{\mathbb{E}}_{4}$'s Disease Treated with Biologics with or Without Previous Seton Placement. Inflammatory Bowel Diseases, 2017, 23, 1860-1866.	1.9	15
27	Endoscopy in inflammatory bowel disease: advances in diseaseÂmanagement. Gastrointestinal Endoscopy, 2017, 86, 952-961.	1.0	5
28	Clinical characterization of in vivo inflammatory bowel disease with Raman spectroscopy. Biomedical Optics Express, 2017, 8, 524.	2.9	41
29	Serum Fatty Acids Are Correlated with Inflammatory Cytokines in Ulcerative Colitis. PLoS ONE, 2016, 11, e0156387.	2.5	51
30	Association Between Affective-Cognitive Symptoms of Depression and Exacerbation of Crohn's Disease. American Journal of Gastroenterology, 2016, 111, 864-870.	0.4	50
31	The Gastroenterologist's Role in Management of Perianal Fistula. Gastrointestinal Endoscopy Clinics of North America, 2016, 26, 693-705.	1.4	6
32	Colestipol granules in the colon: macroscopic and microscopic findings. Histopathology, 2015, 67, 141-142.	2.9	4
33	Cumulative Evidence That Mesenchymal Stem Cells Promote Healing of Perianal Fistulas of Patients With Crohn's Disease–Going From Bench to Bedside. Gastroenterology, 2015, 149, 853-857.	1.3	22
34	Outcomes Following Infliximab Therapy for Pediatric Patients Hospitalized With Refractory Colitis–Predominant IBD. Journal of Pediatric Gastroenterology and Nutrition, 2014, 58, 213-219.	1.8	21
35	Identification of pathologic features associated with "ulcerative colitis-like―Crohn's disease. World Journal of Gastroenterology, 2014, 20, 13139.	3.3	13
36	MTG16 contributes to colonic epithelial integrity in experimental colitis. Gut, 2013, 62, 1446-1455.	12.1	22

#	Article	IF	CITATIONS
37	High-Throughput Multi-Analyte Luminex Profiling Implicates Eotaxin-1 in Ulcerative Colitis. PLoS ONE, 2013, 8, e82300.	2.5	51
38	15â€yearâ€old Girl With Metaplastic Atrophic Gastritis and Enterochromaffinâ€like Cell Hyperplasia. Journal of Pediatric Gastroenterology and Nutrition, 2012, 55, e148-51.	1.8	3
39	Perianal Crohn's Disease—A Gastroenterologist's Perspective. Seminars in Colon and Rectal Surgery, 2012, 23, 117-124.	0.3	1
40	The Evaluation and Treatment of Crohn Perianal Fistulae: EUA, EUS, MRI, and Other Imaging Modalities. Gastroenterology Clinics of North America, 2012, 41, 379-391.	2.2	35
41	Managing Perianal Crohn's Disease. Current Gastroenterology Reports, 2012, 14, 153-161.	2.5	20
42	Proteomic profiling of mucosal and submucosal colonic tissues yields protein signatures that differentiate the inflammatory colitides. Inflammatory Bowel Diseases, 2011, 17, 875-883.	1.9	59
43	Increased serum levels of L-arginine in ulcerative colitis and correlation with disease severity. Inflammatory Bowel Diseases, 2010, 16, 105-111.	1.9	35
44	Endoscopic ultrasound to guide the combined medical and surgical management of pediatric perianal CrohnÊ $\frac{1}{4}$ s disease. Inflammatory Bowel Diseases, 2010, 16, 461-468.	1.9	41
45	Increased expression and cellular localization of spermine oxidase in ulcerative colitis and relationship to disease activity. Inflammatory Bowel Diseases, 2010, 16, 1557-1566.	1.9	40
46	Treatment ofÂFistulizing Inflammatory BowelÂDisease. Medical Clinics of North America, 2010, 94, 19-34.	2.5	8
47	A 31-Year-Old Patient With Colitis and Perianal Disease. Clinical Gastroenterology and Hepatology, 2010, 8, 10-14.	4.4	3
48	Imaging and the Treatment of Crohn's Perianal Fistulas. American Journal of Gastroenterology, 2009, 104, 2987-2989.	0.4	17
49	Survey of gastroenterologists $\hat{E}\frac{1}{4}$ awareness and implementation of AGA guidelines on osteoporosis in inflammatory bowel disease patients: Are the guidelines being used and what are the barriers to their use?. Inflammatory Bowel Diseases, 2009, 15, 1082-1089.	1.9	41
50	Treatment of Fistulizing Inflammatory Bowel Disease. Gastroenterology Clinics of North America, 2009, 38, 595-610.	2.2	18
51	Prevalence and Outcome of Anemia After Restorative Proctocolectomy. Diseases of the Colon and Rectum, 2009, 52, 726-739.	1.3	32
52	Endoscopic Ultrasound and Computed Tomography Predictors of Pancreatic Cancer Resectability. Journal of Gastrointestinal Surgery, 2008, 12, 10-16.	1.7	41
53	To lap or not to lap, that is the question…no longer?. Inflammatory Bowel Diseases, 2008, 14, 1161-1162.	1.9	1
54	What is the optimal maintenance treatment for perianal Crohn $\hat{E}\frac{1}{4}$ s disease?. Inflammatory Bowel Diseases, 2008, 14, S269-S270.	1.9	2

#	Article	IF	Citations
55	A Randomized Prospective Trial of Endoscopic Ultrasound to Guide Combination Medical and Surgical Treatment for Crohn's Perianal Fistulas. American Journal of Gastroenterology, 2008, 103, 2527-2535.	0.4	92
56	The PRECiSE 2 trial of certolizumab pegol, a new PEGylated anti-TNF agent, in the treatment of Crohn's disease: An interview with David A Schwartz, 13 June 2007. Biologics: Targets and Therapy, 2008, 2, 126-8.	3.2	3
57	Nasal Crohn's disease /apheresis. Gastroenterology and Hepatology, 2008, 4, 127-8.	0.1	O
58	Metastatic signet-ring carcinoma of the colon diagnosed by EUS-guided FNA in a patient with Crohn's disease. Gastrointestinal Endoscopy, 2007, 65, 945-947.	1.0	3
59	Small Bowel Adenocarcinoma Complicating Crohn's Disease: Case Series and Review of the Literature. American Surgeon, 2007, 73, 1181-1187.	0.8	51
60	Evolution of the restorative proctocolectomy and its effects on gastrointestinal hormones. International Journal of Colorectal Disease, 2007, 22, 1143-1163.	2.2	17
61	Treatment of perianal fistula and abscess: Crohn's and non-Crohn's. Current Treatment Options in Gastroenterology, 2007, 10, 211-220.	0.8	12
62	Management of Perianal Crohn's Disease. Clinical Gastroenterology and Hepatology, 2006, 4, 426-430.	4.4	28
63	Urine PGE-M: A Metabolite of Prostaglandin E2 as a Potential Biomarker of Advanced Colorectal Neoplasia. Clinical Gastroenterology and Hepatology, 2006, 4, 1358-1365.	4.4	74
64	Pilot Feasibility Studies of Leukocytapheresis With the Adacolumn Apheresis System in Patients With Active Ulcerative Colitis or Crohn Disease. Journal of Clinical Gastroenterology, 2006, 40, 482-489.	2.2	32
65	Endoscopic Ultrasound Diagnosis of Pelvic Lipoma Causing Neurologic Symptoms. Digestive Diseases and Sciences, 2006, 51, 1364-1366.	2.3	7
66	The Successful Use of Adalimumab to Treat Active Crohn's Disease of an Ileoanal Pouch During Pregnancy. Digestive Diseases and Sciences, 2006, 51, 2045-2047.	2.3	85
67	Successful Paternity of a Healthy Child While Taking Methotrexate for Crohn's Disease. American Journal of Gastroenterology, 2006, 101, 2893-2894.	0.4	7
68	Looking in the Rear View Mirror at Pentasa in Active Crohn $\hat{E}^{1}/4$ s Disease: Results May Be Smaller Than They First Appear. Inflammatory Bowel Diseases, 2005, 11 , $73-74$.	1.9	1
69	Calcaneal Ultrasound Bone Densitometry Is Not a Useful Tool to Screen Patients With Inflammatory Bowel Disease at High Risk for Metabolic Bone Disease. Inflammatory Bowel Diseases, 2005, 11, 749-754.	1.9	9
70	Use of Endoscopic Ultrasound to Guide Combination Medical and Surgical Therapy for Patients With Crohn $\hat{E}\frac{1}{4}$ s Perianal Fistulas. Inflammatory Bowel Diseases, 2005, 11, 727-732.	1.9	102
71	The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology, 2002, 122, 875-880.	1.3	984
72	Endoscopic ultrasound techniques for pancreatic cystic neoplasms. Gastrointestinal Endoscopy Clinics of North America, 2002, 12, 709-718.	1.4	4

#	Article	IF	CITATIONS
73	The role of endoscopic ultrasound in hepatobiliary disease. Current Gastroenterology Reports, 2002, 4, 72-78.	2.5	10
74	The rate of false-positive results with EUS-guided fine-needle aspiration. Gastrointestinal Endoscopy, 2002, 56, 868-872.	1.0	19
75	Tofacitinib Adherence and Outcomes in Refractory Inflammatory Bowel Disease. Crohn's & Colitis 360, 0, , .	1.1	0